NCT02736305View on ClinicalTrials.gov

Use of Regorafenib in Recurrent Epithelial Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 3, 2016

Primary Completion Date

November 18, 2019

Study Completion Date

November 18, 2019

Conditions
Ovarian Neoplasms
Interventions
DRUG

Regorafenib

Once a day for 21 days in a 28 days cycle

Trial Locations (1)

169610

National Cancer Centre Singapore, Singapore

All Listed Sponsors
lead

National Cancer Centre, Singapore

OTHER

NCT02736305 - Use of Regorafenib in Recurrent Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter